Updated on 2025/06/23

Information

 

写真a

 
SHIBAHARA DAISUKE
 
Organization
Kyushu University Hospital Respiratory medicine Assistant Professor
School of Medicine Department of Medicine（Concurrent）
Title
Assistant Professor
Profile
臨床：入院・外来診療 研究：肺癌基礎研究 教育：医学生への講義
Homepage
External link

Research Areas

  • Life Science / Respiratory medicine

  • Life Science / Tumor biology

Degree

  • Doctor of Philosophy in Medicine （ 2018.9 University of the Ryukyus ）

  • Medical doctor （ 2007.3 Tohoku University ）

Research History

  • Kyushu University Kyushu University Hospital Respiratory medicine  Assistant Professor 

    2025.4 - Present

  • Kyushu University Department of Respiratory Medicine Assistant Professor 

    2023.4 - 2025.3

    　 More details

    Country：Japan

  • Beth Israel Deaconess Medical Center, Harvard Medical School Oncology  

    2020.8 - 2023.3

    　 More details

    Country：United States

  • University of the Ryukyus Department of Infectious Disease, Respiratory, and Digestive Medicine Staff Physician 

    2020.5 - 2020.7

  • Okinawa Miyako Hospital  Staff Physician 

    2019.4 - 2020.4

  • University of the Ryukyus Department of Infectious Disease, Respiratory, and Digestive Medicine Staff Physician 

    2018.4 - 2019.3

  • University of the Ryukyus Department of Infectious Disease, Respiratory, and Digestive Medicine part-time researcher 

    2014.4 - 2018.3

  • University of the Ryukyus Department of Infectious Disease, Respiratory, and Digestive Medicine Staff Physician 

    2013.4 - 2014.3

  • Okinawa Chubu Tokushukai Hospital Department of Emergency Medicine and Department of General Medicine Staff Physician 

    2009.4 - 2013.3

  • Okinawa Chubu Tokushukai Hospital  Intern 

    2007.4 - 2009.3

▼display all

Education

  • University of the Ryukyus   大学院医学研究科   医学専攻

    2014.4 - 2018.9

  • Tohoku University   医学部   医学科

    2000.4 - 2007.3

Research Interests・Research Keywords

  • Research theme： Mechanisms of drug resistance in lung cancer Tumor immune microenvironment

    Keyword： Lung cancer, resistance, tumor immune microenvironment

    Research period： 2023.4 - 2024.4

Awards

  • Research award of the 81st Annual meeting of Japanese Respiratory society, Kyushu Branch

    2018   Japanese Respiratory society, Kyushu Branch  

Papers

  • Bevacizumab for Brain Radiation Necrosis in Patients With Nonsquamous Nonsmall Cell Lung Cancer Reviewed International journal

    Shibahara D., Tanaka K., Togao O., Shiraishi Y., Yoneshima Y., Iwama E., Yoshitake T., Ishigami K., Okamoto I.

    Clinical Lung Cancer   25 ( 6 )   581 - 586.e3   2024.9   （ ISSN:15257304 ）

    　More details

    Authorship：Lead author,　Corresponding author   Language：English   Publishing type：Research paper (scientific journal)   Publisher：Clinical Lung Cancer  

    The incidence of brain radiation necrosis is increasing in NSCLC patients undergoing radiotherapy for brain metastases. • [11C] methionine–PET and MRS are valuable tools for diagnosing brain radiation necrosis. • Bevacizumab is an effective treatment for brain radiation necrosis in patients with nonsquamous NSCLC.

    DOI： 10.1016/j.cllc.2024.06.010

    Scopus

    PubMed

  • TIP60 is required for tumorigenesis in non-small cell lung cancer Reviewed International journal

    Daisuke Shibahara, Naoki Akanuma, Ikei S. Kobayashi, Eunyoung Heo, Mariko Ando, Masanori Fujii, Feng Jiang, P. Nicholas Prin, Gilbert Pan, Kwok-Kin Wong, Daniel B. Costa, Deepak Bararia, Daniel G. Tenen, Hideo Watanabe, Susumu S. Kobayashi

    Cancer Science   2023.6

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1111/cas.15785

  • Single-Cell Analyses Reveal Diverse Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer Invited Reviewed International journal

    Yukie Kashima, Daisuke Shibahara, Ayako Suzuki, Kyoko Muto, Ikei S. Kobayashi, David Plotnick, Hibiki Udagawa, Hiroki Izumi, Yuji Shibata, Kosuke Tanaka, Masanori Fujii, Akihiro Ohashi, Masahide Seki, Koichi Goto, Katsuya Tsuchihara, Yutaka Suzuki, Susumu S. Kobayashi

    Cancer Research   2021.9

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1158/0008-5472.CAN-20-2811

  • Intrinsic and Extrinsic Regulation of PD-L2 Expression in Oncogene-Driven Non-Small Cell Lung Cancer Invited Reviewed International journal

    Daisuke Shibahara, Kentaro Tanaka, Eiji Iwama, Naoki Kubo, Keiichi Ota, Koichi Azuma, Taishi Harada, Jiro Fujita, Yoichi Nakanishi, Isamu Okamoto

    Journal of Thoracic Oncology   2018.7

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1016/j.jtho.2018.03.012

  • NECTIN4 regulates the cell surface expression of CD155 in non-small cell lung cancer cells and induces tumor resistance to PD-1 inhibitors

    Mizusaki, S; Yoneshima, Y; Iwama, E; Nakashima, T; Ibusuki, R; Shibahara, D; Otsubo, K; Tanaka, K; Okamoto, I

    CANCER IMMUNOLOGY IMMUNOTHERAPY   74 ( 7 )   211   2025.5   （ ISSN:0340-7004 eISSN:1432-0851 ）

    　More details

    Language：English   Publisher：Cancer Immunology Immunotherapy  

    The development of immune checkpoint inhibitors has changed treatment strategies for some patients with non-small cell lung cancer (NSCLC). However, resistance remains a major problem, requiring the elucidation of resistance mechanisms, which might aid the development of novel therapeutic strategies. The upregulation of CD155, a primary ligand of the immune checkpoint receptor TIGIT, has been implicated in a mechanism of resistance to PD-1/PD-L1 inhibitors, and it is therefore important to characterize the mechanisms underlying the regulation of CD155 expression in tumor cells. The aim of this study was to identify a Nectin that might regulate CD155 expression in NSCLC and affect anti-tumor immune activity. In this study, we demonstrated that NECTIN4 regulated the cell surface expression and stabilization of CD155 by interacting and co-localizing with CD155 on the cell surface. In a syngeneic mouse model, NECTIN4-overexpressing cells exhibited increased cell surface CD155 and resistance to anti-PD-1 antibodies. Of note, combination therapy with anti-PD-1 and anti-TIGIT antibodies significantly suppressed tumor growth. These findings provide new insights into the mechanisms of resistance to anti-PD-1 antibodies and suggest that NECTIN4 could serve as a valuable marker in therapeutic strategies targeting TIGIT.

    DOI： 10.1007/s00262-025-04079-z

    Web of Science

    Scopus

    PubMed

  • Renal dysfunction during osimertinib treatment in patients with non-small cell lung cancer positive for EGFR mutations

    Miyazaki, Y; Iwama, E; Ogata, H; Ibusuki, R; Shibahara, D; Otsubo, K; Shiaraishi, Y; Yoneshima, Y; Torisu, K; Okamoto, I

    RESPIRATORY INVESTIGATION   63 ( 3 )   438 - 443   2025.5   （ ISSN:2212-5345 eISSN:2212-5353 ）

    　More details

    Language：English   Publisher：Respiratory Investigation  

    Background: Osimertinib is a standard treatment for non–small cell lung cancer (NSCLC) positive for EGFR activating mutations. Although renal dysfunction associated with osimertinib treatment is reported to be rare, detailed information on this adverse effect is needed because cytotoxic drugs such as pemetrexed are also widely administered for NSCLC but cannot be used in individuals with renal dysfunction. Methods: We retrospectively collected clinical data including the serum creatinine concentration and estimated glomerular filtration rate (eGFR) during osimertinib treatment for 130 NSCLC patients. Results: Serum creatinine and eGFR worsened gradually during osimertinib treatment, with the median value of creatinine at the point of greatest deterioration differing significantly from that at baseline (0.93 versus 0.72 mg/dL, P < 0.01). Seventy patients (54 %) experienced worsening of the CTCAE grade for creatinine increased, with the frequency of patients with grade 1 or 2 being increased significantly (P < 0.01) at the point of greatest deterioration relative to baseline (grade 1, 46.9 % versus 14.6 %; grade 2, 14.6 % versus 0.8 %, respectively). A higher serum creatinine level at baseline was a significant risk factor for worsening of the CTCAE grade (odds ratio of 1.66, P < 0.001). The median serum creatinine and eGFR at 4 weeks after osimertinib discontinuation had improved to levels similar to those for baseline. Conclusions: Renal dysfunction occurred frequently during osimertinib treatment but was ameliorated after drug discontinuation, suggesting that, although renal function should be carefully monitored, its impairment is not likely to affect subsequent chemotherapy in most patients.

    DOI： 10.1016/j.resinv.2025.03.015

    Web of Science

    Scopus

    PubMed

  • Osimertinib readministration for central nervous system metastases in non-small cell lung cancer positive for EGFR activating mutations Invited Reviewed International journal

    Yu Inutsuka, Eiji Iwama, Yoshimasa Shiraishi, Yasuto Yoneshima, Daisuke Shibahara, Kentaro Tanaka, Isamu Okamoto

    Respiratory Investigation   2024.5

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1016/j.resinv.2024.02.001

  • Tracheomediastinal fistula induced by concurrent chemoradiotherapy in small cell lung cancer: A case report and literature review Reviewed International journal

    Yamamoto, Y; Shibahara, D; Mori, T; Otsubo, K; Shiraishi, Y; Yoneshima, Y; Iwama, E; Tanaka, K; Oda, Y; Okamoto, I

    THORACIC CANCER   15 ( 13 )   1106 - 1111   2024.5   （ ISSN:1759-7706 eISSN:1759-7714 ）

    　More details

    Authorship：Corresponding author   Language：English   Publishing type：Research paper (scientific journal)   Publisher：Thoracic Cancer  

    Tracheomediastinal fistula is a rare but life-threatening complication of cancer. We report a case of tracheomediastinal fistula induced by concurrent chemoradiotherapy in limited stage small cell lung cancer. Despite the treatment response, the metastatic paratracheal lymph node increased gradually during concurrent chemoradiotherapy, resulting in the occurrence of tracheomediastinal fistula and mediastinitis. Without any surgical intervention, the patient achieved successful recovery from mediastinitis through antibiotic treatment, although the tracheomediastinal fistula remained open. In this report, we also review previous studies of tracheomediastinal and bronchomediastinal fistulas and summarize the clinical features.

    DOI： 10.1111/1759-7714.15270

    Web of Science

    Scopus

    PubMed

  • YAP mediates resistance to EGF-induced apoptosis in EGFR-mutated non-small cell lung cancer cells Invited Reviewed International journal

    Maako Nakajima, Kentaro Tanaka, Yasuto Yoneshima, Sho Yamashita, Daisuke Shibahara, Eiji Iwama, Isamu Okamoto

    Biochemical and Biophysical Research Communications   2023.11

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1016/j.bbrc.2023.09.067

  • Radiation-induced sarcoma in a 10-year survivor with stage IV EGFR-mutated lung adenocarcinoma

    Daisuke Shibahara, Makoto Furugen, Takuro Ariga, Eriko Atsumi, Hajime Aoyama, Hiroki Maehara, Sadayuki Murayama, Naoki Yoshimi, Fuminori Kanaya, Jiro Fujita

    Respiratory Medicine Case Reports   28   2019.6

    　More details

    Authorship：Lead author  

    DOI： 10.1016/j.rmcr.2019.100889

  • Expression of brain-derived neurotrophic factor and its receptor TrkB is associated with poor prognosis and a malignant phenotype in small cell lung cancer Invited Reviewed International journal

    Shinichi Kimura, Taishi Harada, Kayo Ijichi, Kentaro Tanaka, Renpeng Liu, Daisuke Shibahara, Yuko Kawano, Kohei Otsubo, Yasuto Yoneshima, Eiji Iwama, Yoichi Nakanishi, Isamu Okamoto

    Lung Cancer   2018.6

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1016/j.lungcan.2018.04.005

  • CD44 variant-dependent regulation of redox balance in EGFR mutation-positive non-small cell lung cancer: A target for treatment Invited Reviewed International journal

    Yuko Kawano, Eiji Iwama, Kenji Tsuchihashi, Daisuke Shibahara, Taishi Harada, Kentaro Tanaka, Osamu Nagano, Hideyuki Saya, Yoichi Nakanishi, Isamu Okamoto

    Lung Cancer   2017.11

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1016/j.lungcan.2017.09.008

▼display all

Books

  • EGFR-Directed Therapy in Lung Cancer

    So Yeon Kim, Daniel B. Costa, Daisuke Shibahara, Susumu Kobayashi and Balazs Halmos（Role：Joint author）

    Cambridge University Press  2023.1 

    　More details

    Language：Japanese   Book type：Scholarly book

Presentations

  • Impact of targeted therapy on the tumor immune microenvironment in EGFR-mutated NSCLC International conference

    Daisuke Shibahara

    AACR annual meeting 2025  2025.4  American Association for Cancer Research

    　More details

    Event date： 2025.4

    Language：English   Presentation type：Poster presentation  

    Venue：Chicago, USA   Country：United States  

  • 空間トランスクリプトーム解析から見るEGFR遺伝子変異陽性肺癌の薬剤感受性及び腫瘍微小環境の変化

    中村聡、柴原大典、岸川泰之、中富啓太、中垣憲明、大坪孝平、白石祥理、米嶋康臣 、岩間映二 、田中謙太郎、岡本勇

    日本呼吸器学会学術講演会  2025.4 

    　More details

    Event date： 2025.4

    Language：Japanese   Presentation type：Oral presentation (general)  

    Venue：横浜  

  • がんゲノムプロファイル検査で同定したEGFR-RAD51融合遺伝子陽性肺癌の一例

    石野太雅、柴原大典、大坪孝平、白石祥理、米嶋康臣、岩間映二、田中謙太郎、岡本勇

    日本呼吸器学会九州支部秋季学術講演会  2024.10 

    　More details

    Event date： 2024.10

    Language：Japanese   Presentation type：Oral presentation (general)  

  • EGFR遺伝子変異陽性肺癌におけるDrug tolerant persister細胞による耐性獲得のメカニズム

    柴原大典

    第92回日本呼吸器学会・日本結核 非結核性抗酸菌症学会 九州支部 春季学術講演会  2024.3 

    　More details

    Event date： 2024.4

    Language：Japanese   Presentation type：Symposium, workshop panel (public)  

    Country：Japan  

  • 非小細胞肺癌におけるTIP60の役割

    Daisuke Shibahara, Naoki Akanuma, Ikei S. Kobayashi, Eunyoung Heo, Mariko Ando, Masanori Fujii, Feng Jiang, P. Nicholas Prin, Gilbert Pan, Kwok-Kin Wong, Daniel B. Costa, Deepak Bararia, Daniel G. Tenen, Hideo Watanabe, and Susumu S. Kobayashi

    第64回日本肺癌学会学術集会  2023.11 

    　More details

    Event date： 2024.4

    Language：Japanese   Presentation type：Oral presentation (general)  

    Country：Japan  

  • TIP60 is required for tumorigenesis in non-small cell lung cancer

    Daisuke Shibahara, Naoki Akanuma, Ikei S. Kobayashi, Eunyoung Heo, Mariko Ando, Masanori Fujii, Feng Jiang, P. Nicholas Prin, Gilbert Pan, Kwok-Kin Wong, Daniel B. Costa, Deepak Bararia, Daniel G. Tenen, Hideo Watanabe, and Susumu S. Kobayashi

    第82回日本癌学会学術総会  2023.9 

    　More details

    Event date： 2024.4

    Language：Japanese   Presentation type：Oral presentation (general)  

    Country：Japan  

  • 非扁平上皮非小細胞肺癌における放射線脳壊死に対するベバシズマブの有効性及び安全性

    柴原 大典, 田中 謙太郎, 米嶋 康臣, 白石 祥理, 大坪 孝平, 岩間 映二, 岡本 勇

    肺癌  2024.10  (NPO)日本肺癌学会

    　More details

    Language：Japanese  

  • 化学放射線治療中に気管内穿破をおこした小細胞肺癌の1例

    山本 凱大, 柴原 大典, 白石 祥理, 米嶋 康臣, 池亀 聡, 岩間 映二, 田中 謙太郎, 岡本 勇

    肺癌  2024.6  (NPO)日本肺癌学会

    　More details

    Language：Japanese  

▼display all

Professional Memberships

  • Japanese Society for Internal Medicine

  • Japan Society of Medicine Oncology

  • Japan Lung Cancer Society

  • Japanese Society for Emergency Medicine

  • Japan Respiratory Society

Research Projects

  • EGFR遺伝子変異陽性肺癌における分子標的薬による腫瘍免疫微小環境の変化

    Grant number：25K18857  2025.4 - 2027.3

    Grants-in-Aid for Scientific Research  Grant-in-Aid for Early-Career Scientists

    柴原 大典

    　 More details

    Grant type：Scientific research funding

    CiNii Research

  • 日本化薬株式会社　医学・薬学に関する研究活動への助成

    2024.4 - 2025.3

    日本化薬株式会社 

    　 More details

    Authorship：Coinvestigator(s) 

  • EGFR遺伝子変異陽性肺癌におけるDrug tolerant persister細胞の新規遺伝子の同定

    Grant number：23K19544  2023 - 2024

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research  Grant-in-Aid for Research Activity start-up

    　 More details

    Authorship：Principal investigator  Grant type：Scientific research funding

  • 新日本先進医療研究財団助成

    2023

    　 More details

    Grant type：Donation

  • ２０２３年度　日本イーライリリーイノベーション研究助成

    2023

    　 More details

    Grant type：Donation

Educational Activities

  • 医学生への講義
    大学院生の指導

Class subject

  • 保健学科　医学総論Ⅰ・Ⅱ

    2025.4  

  • 人工呼吸器管理

    2023.10   Second semester

Participation in international educational events, etc.

  • 2025.4

    American Association for Cancer Research

    AACR annual meeting 2025

Travel Abroad

  • 2020.8 - 2023.3

    Staying countory name 1：United States   Staying institution name 1：Beth Israel Deaconess Medical Center/Harvard Medical School

Specialized clinical area

  • Biology / Medicine, Dentistry and Pharmacy / Internal Medicine / Respiratory Medicine

Clinician qualification

  • Specialist

    The Japanese Respiratory Society

  • Specialist

    Japanese Association for Acute Medicine（JAAM）

  • Specialist

    The Japanese Society of Internal Medicine（JSIM）

Year of medical license acquisition

  • 2007